Addtional Effect of Hyperbaric Oxygen to Programmed Physical Activity on Musckoloskeletal Pain in Breast Cancer Elderly

June 17, 2026 updated by: Ali Mohamed Ali ismail, Cairo University

Addtion of Hyperbaric Oxygen to Programmed Physical Activity in Aromatse Inhibtors-linked Musckoloskeletal Pain in Breast Cancer Patients

patienst who survived from breast cancer are prescribed long administraion of aromatase inhbitors.. these inhibitors usually induce musckloskeletal pains. Programmed phsyical activity are reommended to improve these pains but effects of HYperbaric oxygen on these pain was not investigated

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

forty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake were assigned to two groups, group I and group II. the groups received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) but group II additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Egypt
    • Giza Governorate
      • Dokki, Giza Governorate, Egypt, 11432
        • Recruiting
        • Cairo University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • braest cancer survivors
  • patients receiving aramatase inhibitor drugs
  • patients with musckolskeletal pains

Exclusion Criteria:

  • cardiac patients
  • respiratory patients
  • renal patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: group number 1
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) and additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.
Other: hyperbaric therapy and exercise
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) and additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.
Active Comparator: group number 2
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month)
Other: exercise
Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly for 2 month).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
visual analogue scale
Time Frame: it will be measured after 2 months
it self asessmant of pain level
it will be measured after 2 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
worst pain
Time Frame: it will be measured after 2 months
it is a subscore of brief pain inventory
it will be measured after 2 months
pain severity
Time Frame: it will be measured after 2 months
it is a subscore of brief pain inventory
it will be measured after 2 months
pain related interference
Time Frame: it will be measured after 2 months
it is a subscore of brief pain inventory
it will be measured after 2 months
pain score
Time Frame: it will be measured after 2 months
it is a sub score of Western Ontario and McMaster Universities Osteoarthritis
it will be measured after 2 months
stifness score
Time Frame: it will be measured after 2 months
it is a sub score of Western Ontario and McMaster Universities Osteoarthritis
it will be measured after 2 months
fucntion score
Time Frame: it will be measured after 2 months
it is a sub score of Western Ontario and McMaster Universities Osteoarthritis
it will be measured after 2 months
total score of Western Ontario and McMaster Universities Osteoarthritis
Time Frame: it will be measured after 2 months
it is usualy used in patients with arthritic pains
it will be measured after 2 months
Disabilities of the Arm, Shoulder and Hand questionnaire
Time Frame: it will be measured after 2 months
the short form of it used in patients with arthritic pains
it will be measured after 2 months
fatigue severity scale
Time Frame: it will be measured after 2 months
it is used to assess fatigue
it will be measured after 2 months
Short Physical Performance Battery
Time Frame: it will be measured after 2 months
total score used to assess physical performance
it will be measured after 2 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Principal Investigator: Ali MA Ismail, lecturer, Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 7, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

June 17, 2026

First Submitted That Met QC Criteria

June 17, 2026

First Posted (Actual)

June 23, 2026

Study Record Updates

Last Update Posted (Actual)

June 23, 2026

Last Update Submitted That Met QC Criteria

June 17, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB000-14233-82

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe